Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic

Dec 07 2017

• By Emily Hayes

FDA approved background, 3D rendering, blue street sign

Related Content

Novo Nordisk's Victoza Adds CV Benefit Claim, But Not For Primary Prevention

Aug 28 2017

Novo's Semaglutide: Retinopathy Warning Unlikely To Dim Commercial Prospects

Oct 20 2017

Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7

Aug 16 2017

Related Companies

Novo Nordisk A/S

Merck & Co., Inc.

AstraZeneca PLC

Sanofi

Eli Lilly and Company

Additional Topics

Approvals Market Intelligence Regulation Metabolic Disorders BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window